195 related articles for article (PubMed ID: 37090547)
1. Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors.
Xiao Z; Todd L; Huang L; Noguera-Ortega E; Lu Z; Huang L; Kopp M; Li Y; Pattada N; Zhong W; Guo W; Scholler J; Liousia M; Assenmacher CA; June CH; Albelda SM; Puré E
bioRxiv; 2023 Aug; ():. PubMed ID: 37090547
[TBL] [Abstract][Full Text] [Related]
2. Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors.
Xiao Z; Todd L; Huang L; Noguera-Ortega E; Lu Z; Huang L; Kopp M; Li Y; Pattada N; Zhong W; Guo W; Scholler J; Liousia M; Assenmacher CA; June CH; Albelda SM; Puré E
Nat Commun; 2023 Aug; 14(1):5110. PubMed ID: 37607999
[TBL] [Abstract][Full Text] [Related]
3. Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy.
Das S; Valton J; Duchateau P; Poirot L
Front Immunol; 2023; 14():1172681. PubMed ID: 37251405
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast Activation Protein (FAP)-Targeted CAR-T Cells: Launching an Attack on Tumor Stroma.
Bughda R; Dimou P; D'Souza RR; Klampatsa A
Immunotargets Ther; 2021; 10():313-323. PubMed ID: 34386436
[TBL] [Abstract][Full Text] [Related]
5. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager.
de Sostoa J; Fajardo CA; Moreno R; Ramos MD; Farrera-Sal M; Alemany R
J Immunother Cancer; 2019 Jan; 7(1):19. PubMed ID: 30683154
[TBL] [Abstract][Full Text] [Related]
6. Blockade of fibroblast activation protein in combination with radiation treatment in murine models of pancreatic adenocarcinoma.
Gunderson AJ; Yamazaki T; McCarty K; Phillips M; Alice A; Bambina S; Zebertavage L; Friedman D; Cottam B; Newell P; Gough MJ; Crittenden MR; Van der Veken P; Young KH
PLoS One; 2019; 14(2):e0211117. PubMed ID: 30726287
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma.
Kakarla S; Chow KK; Mata M; Shaffer DR; Song XT; Wu MF; Liu H; Wang LL; Rowley DR; Pfizenmaier K; Gottschalk S
Mol Ther; 2013 Aug; 21(8):1611-20. PubMed ID: 23732988
[TBL] [Abstract][Full Text] [Related]
8. Targeting the Interplay Between Cancer Fibroblasts, Mesenchymal Stem Cells, and Cancer Stem Cells in Desmoplastic Cancers.
Chan TS; Shaked Y; Tsai KK
Front Oncol; 2019; 9():688. PubMed ID: 31417869
[TBL] [Abstract][Full Text] [Related]
9. Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells.
Lo A; Wang LS; Scholler J; Monslow J; Avery D; Newick K; O'Brien S; Evans RA; Bajor DJ; Clendenin C; Durham AC; Buza EL; Vonderheide RH; June CH; Albelda SM; Puré E
Cancer Res; 2015 Jul; 75(14):2800-2810. PubMed ID: 25979873
[TBL] [Abstract][Full Text] [Related]
10. Novel banana lectin CAR-T cells to target pancreatic tumors and tumor-associated stroma.
McKenna MK; Ozcan A; Brenner D; Watanabe N; Legendre M; Thomas DG; Ashwood C; Cummings RD; Bonifant C; Markovitz DM; Brenner MK
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36653070
[TBL] [Abstract][Full Text] [Related]
11. Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis.
Hu S; Ma J; Su C; Chen Y; Shu Y; Qi Z; Zhang B; Shi G; Zhang Y; Zhang Y; Huang A; Kuang Y; Cheng P
Acta Biomater; 2021 Nov; 135():567-581. PubMed ID: 34506976
[TBL] [Abstract][Full Text] [Related]
12. FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer.
Liu Y; Sun Y; Wang P; Li S; Dong Y; Zhou M; Shi B; Jiang H; Sun R; Li Z
J Transl Med; 2023 Apr; 21(1):255. PubMed ID: 37046312
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of cancer-associated fibroblast markers at the invasive front and its association with tumor-stroma ratio in colorectal cancer.
Sandberg TP; Stuart MPME; Oosting J; Tollenaar RAEM; Sier CFM; Mesker WE
BMC Cancer; 2019 Mar; 19(1):284. PubMed ID: 30922247
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast activation protein-based theranostics in pancreatic cancer.
Cheng CS; Yang PW; Sun Y; Song SL; Chen Z
Front Oncol; 2022; 12():969731. PubMed ID: 36263225
[TBL] [Abstract][Full Text] [Related]
15. Development of Nectin4/FAP-targeted CAR-T cells secreting IL-7, CCL19, and IL-12 for malignant solid tumors.
Li F; Zhao S; Wei C; Hu Y; Xu T; Xin X; Zhu T; Shang L; Ke S; Zhou J; Xu X; Gao Y; Zhao A; Gao J
Front Immunol; 2022; 13():958082. PubMed ID: 36479116
[TBL] [Abstract][Full Text] [Related]
16. FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via STAT3-CCL2 Signaling.
Yang X; Lin Y; Shi Y; Li B; Liu W; Yin W; Dang Y; Chu Y; Fan J; He R
Cancer Res; 2016 Jul; 76(14):4124-35. PubMed ID: 27216177
[TBL] [Abstract][Full Text] [Related]
17. Imaging aspects of the tumor stroma with therapeutic implications.
Narunsky L; Oren R; Bochner F; Neeman M
Pharmacol Ther; 2014 Feb; 141(2):192-208. PubMed ID: 24134903
[TBL] [Abstract][Full Text] [Related]
18. Specific inhibition of fibroblast activation protein (FAP)-alpha prevents tumor progression in vitro.
Teichgräber V; Monasterio C; Chaitanya K; Boger R; Gordon K; Dieterle T; Jäger D; Bauer S
Adv Med Sci; 2015 Sep; 60(2):264-72. PubMed ID: 26057860
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic Tumor Microenvironment.
Wang K; He H
Adv Exp Med Biol; 2020; 1296():243-257. PubMed ID: 34185297
[TBL] [Abstract][Full Text] [Related]
20. Stromal Modulation Reverses Primary Resistance to Immune Checkpoint Blockade in Pancreatic Cancer.
Zhao J; Xiao Z; Li T; Chen H; Yuan Y; Wang YA; Hsiao CH; Chow DS; Overwijk WW; Li C
ACS Nano; 2018 Oct; 12(10):9881-9893. PubMed ID: 30231203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
